Reduced circulating adiponectin levels are associated with the metabolic syndrome independently of obesity, lipid indices and serum insulin levels: A cross-sectional study

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Ntzouvani, Agathi ^a   Fragopoulou, Elisabeth ^a   Panagiotakos, Demosthenes ^a   Pitsavos, Christos ^b   Antonopoulou, Smaragdi ^a  

^a HAROKOPIO UNIVERSITY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Adiponectin; Interleukin 6; Mediation effect; Metabolic syndrome

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; ADIPOQ PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; BLOOD; GREECE; MIDDLE AGED;

ADIPONECTIN; ADULT; AGED; CROSS-SECTIONAL STUDIES; FEMALE; GREECE; HUMANS; INTERLEUKIN-6; MALE; METABOLIC SYNDROME X; MIDDLE AGED;

EID: 84983672173     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0311-7     Document Type: Article

References (58)

1. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith Jr SC, International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung, and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.
2. Nomikos T, Panagiotakos D, Georgousopoulou E, Metaxa V, Chrysohoou C, Skoumas I, Antonopoulou S, Tousoulis D, Stefanadis C, Pitsavos C, ATTICA Study group. Hierarchical modelling of blood lipids' profile and 10-year (2002-2012) all cause mortality and incidence of cardiovascular disease: the ATTICA study. Lipids Health Dis. 2015;14:108.
3. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, et al. Association/National Heart, Lung, and Blood Institute Scientific Statement Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
4. Pitsavos C, Panagiotakos DB, Chrysohoou C, Stefanadis C. Study protocol. Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health. 2003;3:32.
5. Athyros VG, Bouloukos VI, Pehlivanidis AN, Papageorgiou AA, Dionysopoulou SG, Symeonidis AN, Petridis DI, Kapousouzi MI, Satsoglou EA, Mikhailidis DP, for The MetS-Greece Collaborative Group, et al. The prevalence of the metabolic syndrome in Greece: The MetS-Greece Multicentre Study. Diabetes Obes Metab. 2005;7:397-405.
6. Panagiotakos DB, Pitsavos C, Das UN, Skoumas Y, Stefanadis C. The implications of anthropometric, inflammatory and glycaemic control indices in the epidemiology of the metabolic syndrome given by different definitions: a classification analysis. Diabetes Obes Metab. 2007;9:660-8.
7. Bener A, Yousafzai MT, Darwish S, Al-Hamaq A, Nasralla EA, Abdul-Ghani M. Obesity index that better predict metabolic syndrome: body mass index, waist circumference, waist hip ratio, or waist height ratio. J Obes. 2013;269038:9.
8. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? Clin Endocrinol Metab. 2013;98:E1610-E9.
9. Marques-Vidal P, Bastardot F, von Känel R, Paccaud F, Preisig M, Waeber G, Vollenweider P. Association between circulating cytokine levels, diabetes and insulin resistance in a population-based sample (CoLaus study). Clin Endocrinol (Oxf). 2013;78:232-41.
10. Weiss TW, Arnesen H, Seljeflot I. Components of the Interleukin-6 trans-signaling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metab Clin Exp. 2013;62:1008-13.
11. Hung J, McQuillan BM, Thompson PL, Beilby JP. Circulating adiponectin levels associate with inflammatory markers, insulin resistance and metabolic syndrome independent of obesity. Int J Obes (Lond). 2008;32:772-9.
12. Bountziouka V, Bathrellou E, Giotopoulou A, Katsagoni C, Bonou M, Vallianou N, Barbetseas J, Avgerinos PC, Panagiotakos DB. Development, repeatability and validity regarding energy and macronutrient intake of a semiquantitative food frequency questionnaire: Methodological considerations. Nutr Metab Cardiovasc Dis. 2012;22:659-67.
13. Panagiotakos DB, Pitsavos C, Stefanadis C. Dietary patterns: a Mediterranean diet score and its relation to clinical and biological markers of cardiovascular disease risk. Nutr Metab Cardiovasc Dis. 2006;16:559-68.
14. Panagiotakos DB, Pitsavos C, Chrysohoou C, Skoumas J, Masoura C, Toutouzas P, Stefanadis C. Effect of exposure to secondhand smoke on markers of inflammation: the ATTICA study. Am J Med. 2004;116:145-50.
15. Barnoya J, Glantz SA. Cardiovascular effects of secondhand smoke. Nearly as large as smoking. Circulation. 2005;111:2684-98.
16. Papathanasiou G, Georgoudis G, Papandreou M, Spyropoulos P, Georgakopoulos D, Kalfakakou V, Evangelou A. Reliability measures of the short International Physical Activity Questionnaire (IPAQ) in Greek young adults. Hellenic J Cardiol. 2009;50:283-94.
17. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
18. Preacher KJ, Hayes AF. SPSS and SAS procedures for estimating indirect effects in simple mediation models. Behav Res Methods Instrum Comput. 2004;36:717-31.
19. Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Müller M. Package 'pROC': Display and Analyze ROC Curves (Version 1.8), 2015. Available at: https://cran.r-project.org/web/packages/pROC/pROC.pdf. Accessed 24 Mar 2016.
20. Maury E, Brichard SM. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome. Mol Cell Endocrinol. 2010;314:1-16.
21. Scicchitano P, Cameli M, Maiello M, Modesti PA, Muiesan ML, Novo S, Palmiero P, Saba PS, Pedrinelli R, Ciccone MM, on behalf of the "Gruppo di Studio Ipertensione, Prevenzione e Riabilitazione", Società Italiana di Cardiologia. Nutraceuticals and dyslipidaemia: Beyond the common therapeutics. J Funct Foods. 2014;6:11-32.
22. You T, Yang R, Lyles MF, Gong D, Nicklas BJ. Abdominal adipose tissue cytokine gene expression: relationship to obesity and metabolic risk factors. Am J Physiol Endocrinol Metab. 2005;288:E741-E7.
23. You T, Nicklas BJ, Ding J, Penninx BWJH, Goodpaster BH, Bauer DC, Tylavsky FA, Harris TB, Kritchevsky SB, for the Health, Aging and Body Composition Study, et al. The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity. J Gerontol A Biol Sci Med Sci. 2008;63:414-9.
24. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, Klein S, Coppack SW. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82:4196-200.
25. Lago F, Dieguez C, Gómez-Reino J, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Cytokine Growth Factor Rev. 2007;18:313-25.
26. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y, Brichard SM. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001;288:1102-7.
27. Ruan H, Dong LQ. Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol. 2016;8:101-9.
28. Caselli C. Role of adiponectin system in insulin resistance. Mol Genet Metab. 2014;113:155-60.
29. Tsao TS. Assembly of adiponectin oligomers. Rev Endocr Metab Disord. 2014;15:125-36.
30. Ciccone MM, Faienza MF, Altomare M, Nacci C, Montagnani M, Federica V, Cortese F, Gesualdo M, Zito A, Mancarella R, Leogrande D, Viola D, Scicchitano P, Giordano P. Endothelial and Metabolic Function Interactions in Overweight/ Obese Children: The Role of High-Molecular Weight Adiponectin. J Atheroscler Thromb. 2016. [Epub ahead of print].
31. Kizer JR, Arnold AM, Benkeser D, Ix JH, Djousse L, Zieman SJ, Barzilay JI, Tracy RP, Mantzoros CS, Siscovick DS, Mukamal KJ. Total and high-molecular-weight adiponectin and risk of incident diabetes in older people. Diabetes Care. 2012;35:415-23.
32. Saito I, Yamagishi K, Chei CL, Cui R, Ohira T, Kitamura A, Kiyama M, Imano H, Okada T, Kato T, Hitsumoto S, Ishikawa Y, Tanigawa T, Iso H. Total and high molecular weight adiponectin levels and risk of cardiovascular disease in individuals with high blood glucose levels. Atherosclerosis. 2013;229:222-7.
33. Fargnoli JL, Sun Q, Olenczuk D, Qi L, Zhu Y, Hu FB, Mantzoros CS. Resistin is associated with biomarkers of inflammation while total and HMW adiponectin are associated with biomarkers of inflammation, insulin resistance, and endothelial function. Eur J Endocrinol. 2010;162:281-8.
34. Nakashima R, Yamane K, Kamei N, Nakanishi S, Kohno N. Low serum levels of total and high-molecular-weight adiponectin predict the development of metabolic syndrome in Japanese-Americans. J Endocrinol Invest. 2011;34:615-9.
35. von Frankenberg AD, do Nascimento FV, Gatelli LE, Nedel BL, Garcia SP, de Oliveira C, Saddi-Rosa P, Reis AF, Canani LH, Gerchman F. Major components of metabolic syndrome and adiponectin levels: a cross-sectional study. Diabetol Metab Syndr. 2014;6:26.
36. Knights AJ, Funnell A, Pearson R, Crossley M, Bell-Anderson K. Adipokines and insulin action. A sensitive issue. Adipocyte. 2014;3:88-96.
37. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease detection and prevention. Circulation. 2003;107:363-9.
38. Maachi M, Piéroni L, Bruckert E, Jardel C, Fellahi S, Hainque B, Capeau J, Bastard JP. Systemic low grade inflammation is related to both circulating and adipose tissue TNF-a, leptin and IL-6 levels in obese women. Int J Obes. 2004;28:993-7.
39. Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. Inflamm Res. 2009;58:727-36.
40. Shehzad A, Iqbal W, Shehzad O, Lee YS. Adiponectin: Regulation of its production and its role in human diseases. Hormones (Athens). 2012;11:8-20.
41. Sun H, Zhang Y, Gao P, Li Q, Sun Y, Zhang J, Xu C. Adiponectin reduces C-reactive protein expression and downregulates STAT3 phosphorylation induced by IL-6 in HepG2 cells. Mol Cell Biochem. 2011;347:183-9.
42. Yuan G, Jue Jia J, Di L, Zhou L, Dong S, Ye J, Wang D, Yang L, Wang J, Li L, Yang Y, Mao C, Chen M. Effects of C-reactive protein on adipokines genes expression in 3 T3-L1 adipocytes. Biochem Biophys Res Commun. 2012;424:462-8.
43. Vilarrasa N, Vendrell J, Maravall J, Broch M, Estepa A, Megia A, Soler J, Simón I, Richart C, Gómez JM. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol (Oxf). 2005;63:329-35.
44. Gannagé-Yared MH, Khalife S, Semaan M, Fares F, Jambart S, Halaby G. Serum adiponectin and leptin levels in relation to the metabolic syndrome, androgenic profile and somatotropic axis in healthy non-diabetic elderly men. Eur J Endocrinol. 2006;155:167-76.
45. Maahs DM, Ogden LG, Snell-Bergeon JK, Kinney GL, Wadwa RP, Hokanson JE, Dabelea D, Kretowski A, Eckel RH, Rewers M. Determinants of serum adiponectin in persons with and without type 1 diabetes. Am J Epidemiol. 2007;166:731-40.
46. Salas-Salvadó J, Granada M, Bulló M, Corominas A, Casas P, Foz M. Plasma adiponectin distribution in a Mediterranean population and its association with cardiovascular risk factors and metabolic syndrome. Metabolism. 2007;56:1486-92.
47. Thewissen MM, Damoiseaux JG, Duijvestijn AM, van Greevenbroek MM, van der Kallen CJ, Feskens EJ, Blaak EE, Schalkwijk CG, Stehouwer CD, Tervaert JWC, et al. Abdominal fat mass is associated with adaptive immune activation: the CODAM study. Obesity (Silver Spring). 2011;19:1690-8.
48. Thorand B, Baumert J, Döring A, Herder C, Kolb H, Rathmann W, Giani G, Koenig W, for the KORA Group. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis. 2006;184:216-24.
49. Jung UJ, Choi MS. Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-223.
50. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med. 2008;14:741-51.
51. Hoene M, Weigert C. Appetite regulatory peptides. The role of interleukin-6 in insulin resistance, body fat distribution and energy balance. Obes Rev. 2008;9:20-9.
52. Fisman EZ, Tenenbaum A. Adiponectin: a manifold therapeutic target for metabolic syndrome, diabetes, and coronary disease? Cardiovasc Diabetol. 2014;13:103.
53. Henneman P, Janssens ACJW, Zillikens MC, Frolich M, Frants RR, Oostra BA, van Duijn CM, van Dijk KW. Menopause impacts the relation of plasma adiponectin levels with the metabolic syndrome. J Intern Med. 2010;267:402-9.
54. Koh SB, Yoon J, Kim JY, Yoo BS, Lee SH, Park JK, Choe KH. Relationships between serum adiponectin with metabolic syndrome and components of metabolic syndrome in non-diabetic Koreans: ARIRANG study. Yonsei Med J. 2011;52:234-41.
55. Juonala M, Saarikoski LA, Viikari J, Oikonen M, Lehtimäki T, Lyytikäinen LP, Huupponen R, Magnussen CG, Koskinen J, Laitinen T, et al. A longitudinal analysis on associations of adiponectin levels with metabolic syndrome and carotid artery intima-media thickness. The cardiovascular risk in young Finns study. Atherosclerosis. 2011;217:234-9.
56. Kim JY, Ahn SV, Yoon JH, Koh SB, Yoon J, Yoo BS, Lee SH, Park JK, Choe KH, Guallar E. Prospective study of serum adiponectin and incident metabolic syndrome: the ARIRANG study. Diabetes Care. 2013;36:1547-53.
57. Hung J, McQuillan BM, Chapman C, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol. 2005;25:1268-73.
58. Choi KM, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, Kim NH, Choi DS, Baik SH. Serum adiponectin, interleukin-10 levels and inflammatory markers in the metabolic syndrome. Diabetes Res Clin Pract. 2007;75:235-40.